 SEATTLE, Aug. 5, 2021 PRNewswire -- CTI BioPharma Corp. Nasdaq: CTIC today reported its financial results for the second quarter ended June 30, 2021. This past quarter, we continued to advance pacritinib towards a potential U.S. approval and commercial launch this year. 